US FDA consults on e-submission of summary-level data to facilitate inspection of drug trial sites
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is inviting feedback from drug makers on a standardised electronic format for submitting summary-level data from individual clinical trial sites to facilitate timely inspection of these sites during the review of marketing applications1,2.